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Purpose: To evaluate whether or not brain single photon emission computed
tomography (SPECT) with Tc-99m MIBI or Tc-99m ECD (ethyl cysteinate
dimer) can detect any abnormality in patients with definite multiple sclerosis
(MS). We then compared these values with the results of T1, T2, and
fluid-attenuated inversion recovery in magnetic resonance imaging (MRI).
Materials and Methods: A total of 16 patients with proved MS were
enrolled in the study, and the MRI with and without gadolinium contrast and
also brain SPECT with Tc-99m MIBI (8 cases) or Tc-99m ECD (8 other
cases) were performed.
Results: MRI studies was performed in 16 patients (13 women and 3 men,
aged 16–38 years) and an average of 10.47, 3.7, 5.3, 1.7, and 0.9 lesions was
found in respect in periventricular white matter, juxtacortical white matter,
corpus callosum, cerebellar peduncles, and brainstem, whereas brain SPECT
with Tc-99m MIBI or Tc-99m ECD detected no abnormality. In addition, 6
cases had some degree of contrast enhancement.
Conclusions: It seems that brain SPECT with Tc-99mMIBI or Tc-99m ECD
would not improve this insufficiency. The small sizes of some plaques,
particularly in chronic atrophic form of lesions, and the possibility of deeper
anatomic positions of plaques can explain to some extent why the MS lesions
were impossible to delineate on brain scan, although additional studies are
needed.
Key Words: multiple sclerosis, brain SPECT, Tc-99m MIBI, Tc-99m
ECD, magnetic resonance imaging
(Clin Nucl Med 2010;35: 682–686)
Demyelination of white matter (WM) in the central nervoussystem (CNS) is the hallmark of multiple sclerosis (MS). There
has been a great amount of modifications in diagnosis of MS;
although Schumacher criteria contains only clinical observations,
and Poser et al have included paraclinical evaluations like cerebro-
spinal fluid (CSF) examination, oligoclonal banding or intrathecal
IgG state, and computed tomography (CT) with little respect to
magnetic resonance imaging (MRI),1 Mc Donald criteria extensively
rely on MRI. Clinical evidence or imaging testimony of 2 separated
lesions in CNS (dissociation in place) and/or presence of distinct lesions
during a period of time (dissociation in time) are highly restricted to
MS.2 Gean-Marton et al have also proposed that lesions in midsagittal
long repetition time (TR)/short echo time (TE) images and involvement
of corpus callosum are highly specific for MS rather than other periven-
tricular WM disorders.3 Fast spin-echo (FSE), fluid-attenuated inver-
sion recovery (FLAIR) FSE, and short tau inversion recovery FSE are
among the other modifications to MRI, which ameliorate the sensitivity
and specificity of indicated MS plaques.4 A combinational set of
textural features application in image volumetric interpretation has also
shown to be more accurate in distinguishing MS plaques from the
normal appearing WM and normal WM.5
The most challenging concern regarding the MRI application
for MS evaluation is the commonly poor correlation between MRI
indicated levels of disease and clinical manifestations or expanded
disability status scale in which the degree of lesions reported in MRI
is always worse than what the extent of clinical symptoms are.6
Although early anticipation of potential deterioration of disease is
important for clinical management,7 little prognostic capability of
MRI where it cannot predict the relapse or consequent burden is
another insufficiency of this procedure.8 Intracortical lesions which
have been shown to be abundant in MS patients and may elicit
cognitive deficit usually remains obscure on MR imaging.9
Abnormal brain scan is reported in MS and other demyeli-
nating disorders. Gize and Mishkin have described focal abnormal-
ities with 203 Hg-chlormerodrin or 99mTcO4 brain scan in 36% of
cases with acute MS10 and Miller and Potsaid have also reported a
case of MS with vascular infiltration in which 99mTcO4 scanning has
revealed discrete area of hyperactivity and hyperintensity in occipital
regions of the brain.11 On the other hand, Moses et al studying 14
patients in their acute exacerbation and 5 cases in their quiescent phase
of the disease, who were suffering from definite MS for several years
and a moderate to severe state of disability, concluded that 99mTcO4
scanning is unlikely to detect a state of brain abnormality in MS.12
In this study, we aim to evaluate whether or not brain SPECT
scintigraphy with Tc-99m MIBI or Tc-99m ECD can detect any
abnormality in patients with definite MS. We then compared these
values with the results of T1, T2, and FLAIR in MRI.
MATERIALS AND METHODS
Our study population consisted of 16 patients with definite
MS diagnosed on the basis of clinical signs and symptoms localized
to at least 2 anatomic regions of the CNS and at least initially a
course of relapses and remissions separated by at least 1 month.
Each patient underwent a complete neurologic examination.
MRI was performed for all 16 cases while brain SPECT with
Tc-99m ECD was performed for 8 cases and brain SPECT with
Tc-99m MIBI for the other 8 subjects.
Brain SPECT With Tc-99m ECD
A commercial ECD preparation was used in 8 patients. The
labeling and quality control procedures were performed according to
the manufacturer’s instructions. All subjects had an intravenous (IV)
line established while they were lying down, with their eyes closed
and ears unplugged, in a quiet darkened room with low ambient sound
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and light. After approximately 30 minutes, each subject received a
740-MBq (20 mCi) IV injection of tracer while they were still lying
down in the same quiet darkened room. One hour after IV injection of
740 MBq (20 mCi) Tc-99m ECD in a room with low level of ambient
light and minimal background noise, SPECT procedure was performed.
Scans were performed on a dual head ADAC camera (ADAC Genesys,
Malpitas, CA), equipped with a pair of low energy, high resolution
collimators. The full-width at half maximum (FWHM) of this system,
as measured in-house, was 12-mm for Tc-99m. Standard head posi-
tioning was based on uniform alignment of the external auditory meatus
FIGURE 1. MRI and SPECT with Tc-99m ECD outcomes in a 26-year-old female patient; (A): axial T2 and (B) postcontrast T1-
weighted images show multiple demyelinating lesions in bilateral cerebral WM, some of them showing enhancement after
contrast injection. C, Brain SPECT with Tc-99m ECD shows no remarkable abnormality.
Clinical Nuclear Medicine • Volume 35, Number 9, September 2010 SPECT Versus MRI in Multiple Sclerosis
© 2010 Lippincott Williams & Wilkins www.nuclearmed.com | 683
using automated table positioning and camera-to-head-detector ratio
values. The total acquisition time was 35 minutes for each study.
Images were acquired in a 64  64  64 three-dimensional pixel
matrix at 64 steps, 30 seconds each step. Before reconstruction of the
images, attenuation correction of the images was carried out by the
Chang method (attenuation coefficient 0.12 cm1). The data were then
processed by back projection and filtered by Butterworth filter, using a
Nyquist frequency cut-off of 0.5 and order of 5. Images were recon-
structed and displayed in all 3 orthogonal planes. SPECT results were
analyzed by 2 experienced nuclear medicine physicians, who were not
aware of the patient’s medical history, nor had information about the
MRI results; the frontal, parietal, temporal, occipital cortex, basal
ganglia, brainstem, and cerebellum were analyzed systematically. Nor-
mal brain SPECT findings included homogeneous rCBF in the men-
FIGURE 2. MRI and SPECT with Tc-99m MIBI outcomes in a 19-year-old woman. A, Axial FLAIR MR image shows multiple hy-
perintense lesions in bilateral periventricular cerebral white matter consistent with patients known multiple sclerosis. After con-
trast injection, no significant abnormal enhancement could be identified. B, Brain SPECT with Tc-99m MIBI shows no remark-
able abnormality.
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tioned regions without focal hypoperfusion or visible asymmetry. Ab-
normal brain SPECT findings were defined as heterogeneous rCBF
with focal hypoperfusion or visible asymmetry in at least 2 consecutive
slices in 2 sections.13
Brain SPECT With Tc-99m MIBI
A commercial MIBI preparation was used in other 8 patients.
The labeling and quality control procedures were performed accord-
ing to the manufacturer’s instructions. Each patient received 740-
MBq (20 mCi) Tc-99m MIBI and within 30 to 60 minutes following
injection the imaging was started. All other acquisition protocol was
the same as above.
Magnetic Resonance Imaging
MR imaging was performed with a l.5-T Signal imager
(General Electric, Milwaukee) with 3 spin-echo pulse sequences
emphasizing T1, T2-weighted and FLAIR weighted information.
We defined active lesions as those that enhanced after the IV
injection of gadolinium. The scans and MRI had been performed
within 1 week interval.
The study complies with the doctrine of declaration of Hel-
sinki and was approved by the institutional ethics committee of
Bushehr University of Medical Sciences. Subjects enrolled in the
study were previously informed and had signed a written consent.
RESULTS
We evaluated 16 patients (13 women and 3 men, aged 16–38
years) with definite MS based on clinical signs and symptoms localized
to at least 2 anatomic regions of the central nervous system and at least
initially a course of relapses and remissions separated by at least 1
month. Clinical activity was defined as a recent change in neurologic
signs or symptoms (within 4 weeks before the study) or a clear-cut,
steady history of chronic progressive disease. All patients with diag-
noses of inactive MS had been free of new neurologic symptoms for
more than 4 months. Eight patients had inactive clinically.
MRI studies was performed in all 16 patients and an average
of 10.47, 3.7, 5.3, 1.7, and 0.9 lesions was found in periventricular
WM, juxtacortical WM, corpus callosum, cerebellar peduncles, and
brainstem, respectively (Figs. 1A, B and 2A). Six cases had some
degree of contrast enhancement.
Patients were randomly divided into 2 groups of 8 patients each
and brain SPECT with either Tc-99m ECD or Tc-99m MIBI was
applied. We observed abnormal brain scan neither in the former (Fig.
1C) nor in the later (Fig. 2B) assessment. Table 1 summarizes the
corresponding outcomes of MRI and SPECT in each patient analyzed
by 2 nuclear medicine specialists and 2 radiologists separately.
DISCUSSION
Although MR imaging provides a sensitive diagnostic tools
for MS, it is noteworthy that the manifestation of plaques on MRI
imaging is not specific for MS.2,14 Koziol et al have also describe that
appearance of neither enhancing lesions, new enhancing lesions, nor
hypointense lesions (black holes) in T1-weight MRI could anticipate
the imminent clinical exacerbation of relapse-remitting MS; however,
the absence of abovementioned markers in MRI is contributed to a
more desirable state of the disease.7 Miki et al, using a validated highly
reproducible computerized image analysis software on T2-sagittal MRI
results, stated that in spite of continuous increment, the lesion volumes
did not correlate with the extent of disability in relapse-remitting
MS.15,16 While a moderate connection between spinal cord lesion
extent and expanded disability status and sensory deficit is found in MS
patients, there is inconsistency between appearance of lesions on MRI
and clinical manifestations of myelopathy.17
Due to pathophysiology of MS and role of inflammation and
disrupted of blood-brain barrier (BBB) and also based on the previous
papers concerning of Tc-99m MIBI in these situation, we hypothesized
that it may be valuable in this disease. Demyelinated regions in the
brain did not result in abnormalities on none of the brain scans including
brain SPECT with Tc-99m MIBI or Tc-99m ECD. Our results are
somehow consistent with Moses et al study with regard to failure of
brain scanning in plaques visualization; however, they have evaluated
the relapse-remitting form of MS on brain scan with Tc-99m.12 The
small sizes of some plaques which could be as small as 1 mm,
particularly in chronic atrophic form of lesions, and the possibility of
deeper anatomic positions of plaques can to some extent explain why
the ms lesions were impossible to delineate on brain scan11,18; however,
other investigations using SPECT modality with higher spatial resolu-
tion is required to evaluate these findings.
Gadolinium enhancement in both CT and MRI have also been
applied to demonstrate a disrupted BBB in inflammatory process of
MS in which the proinflammatory state of active disease and
subsequent extravasation of the contrast result in both higher num-
ber of lesions detected and more intense foci.19,20 Gadolinium
enhancement offers a diagnostic tool to differentiate between the
active and silent states of MS and is likely to provide a superior
sensitivity and specificity than CSF examination and high Iodine CT
(HICT)20,21; however, contrast-mediated higher intensity of foci is
not confined to MS and is also observed in vasculitis as well as
neurosarcoidosis and most infections21 and enhancement study may
overestimate the number of active lesions.22 In addition, triple dose
contrast has led not only to higher incidence of lesion detection on
MRI but also a large number of false-positive lesions due to flow
artifacts.23,24 Inflammation is not present in the chronic form of MS
which is deduced from the lack of contrast enhancement in persis-
tent lesions.25 The absence of inflammatory edema in chronic form2
can be the reason behind the inefficiency of MIBI contrast enhance-
ment in visualization of plaques in our study.
It seems that brain SPECT with Tc-99m MIBI or Tc-99m
ECD would not improve this insufficiency. It is of interest to state
TABLE 1. Number of Lesions Detected in Each Anatomical Region in Different Patients
Anatomical Region 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total
MRI Periventricular WM 13 26 0 2 26 4 3 10 15 24 5 14 12 6 6 4 170
Juxtacortical WM 3 5 1 0 8 4 2 4 4 7 0 8 6 2 2 2 58
Corpus callosum 5 8 1 2 13 5 4 8 3 12 2 4 5 2 6 4 84
Cerebellar peduncles 2 2 0 1 3 1 1 4 0 2 0 1 3 1 4 2 27
Brainstem 0 0 0 0 2 2 1 2 0 1 0 2 1 0 2 0 13
MIBI NL NL NL NL NL NL NL NL
ECD NL NL NL NL NL NL NL NL
WM indicates white matter; NL, no lesion; ECD, ethyl cysteinate dimer.
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that other techniques at the field of nuclear medicine are promising
regarding the evaluation of MS and stage designation of the disease;
positron emission tomography (PET) of peripheral benzodiazepine
receptor (PBR) with 11C-PK11195 radionucleotide had revealed that
this receptors is down-regulated at chronic disappearance of myelin and
noninflammatory microglia stimulation in chronic degenerative phase
and myelin replacement by axonal scars, whereas PBR is up-regulated
whenever there is an active stage of the disease or a relapse is
impending.26 Proton MR assessment of the N-acetylaspartate which
reflects direct axonal loss diminishes in MS and its dynamics may profit
clinicians not only in early estimation of disease course and severity, but
also in treatment decisions and patient follow up.8 Magnetization
transfer (MT) imaging seems to be more specific for myelin where the
MT ratio is directly proportional to myelin molecules; a decrement in
MT ratio represents a structural or pathologic myelin loss and tissue
injury, whereas an increment in this value indicates either an active
inflammatory process or remyelination status.18,27 Average water dif-
fusion coefficient is shown to be capable of distinguishing between
relapsing-remitting and secondary-progressive lesions and is well cor-
related with the extent of standardized measure of disability in individ-
ual MS subjects.28
Connective tissue disease is considered one of the more impor-
tant differential diagnosis of MS, which even after multiple diagnostic
studies, includingMRI, CSF examination, visual evoked potentials, and
autoantibody marker, a number of patients with systemic autoimmune
disease can be misdiagnosed for MS.29 Several studies have revealed
hypoperfusion area in brain SPECT in connective tissue disease with
neurologic manifestation, like systemic lupus erythematous,30 Behcet
disease,31 Sjoegren syndrome,31 and antiphospholipid syndrome.32
With regard to our findings about the absence of SPECT abnormalities
in MS patients, it seem that brain SPECT might be useful in discrim-
ination ofMS from connective tissue disorder, base on the evidence that
hypoperfusion in SPECT is against the diagnosis of MS, although
normal SPECT does not support it.
CONCLUSIONS
It seems that brain SPECT with Tc-99m MIBI or Tc-99m
ECD would not improve this insufficiency. The small sizes of some
plaques, particularly in chronic atrophic form of lesions, and the
possibility of deeper anatomic positions of plaques can to some
extent explain why the MS lesions were impossible to delineate on
brain scan. It seems that brain SPECT might be useful in discrim-
ination of MS from connective tissue disorder, based on the evi-
dence that hypoperfusion in SPECT is against the diagnosis of MS,
although normal SPECT does not support it.
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